Technical Analysis for MXDHF - Mdxhealth Sa

Grade Last Price % Change Price Change
grade F 0.74 -22.11% -0.2100
MXDHF closed down 22.11 percent on Wednesday, July 15, 2020, on 54 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical MXDHF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -22.11%
MACD Bullish Signal Line Cross Bullish -22.11%
Narrow Range Bar Range Contraction -22.11%
Wide Bands Range Expansion -22.11%
Gapped Up Strength -22.11%
Up 3 Days in a Row Strength -22.11%
Up 4 Days in a Row Strength -22.11%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -17.78%
Stochastic Buy Signal Bullish -17.78%
Older signals for MXDHF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for prostate, bladder, kidney, cervical, and brain cancers. Its products include ConfirmMDx, a tissue-based epigenetic test for prostate cancer; SelectMDx, a urine-based mRNA test for prostate cancer; and AssureMDx bladder cancer detection test for patients with unresolved hematuria. The company's preclinical development products comprise InformMDx, a tissue-based gene expression panel for prostate cancer; SelectMDx assay to a point of care testing platform; and MonitorMDx, a blood-based test for prostate cancer. It has collaboration agreement with 3D Signatures Inc. to evaluate prognostic test candidate for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.
Medicine RTT Cancer Clinical Medicine European Union Prostate Cancer Infectious Causes Of Cancer Gene Expression Molecular Diagnostics Bladder Cancer Cancer Detection Epigenomics Ag Histopathology

Is MXDHF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 6.15
52 Week Low 0.645
Average Volume 1,867
200-Day Moving Average 0.0000
50-Day Moving Average 1.4293
20-Day Moving Average 1.0327
10-Day Moving Average 0.8899
Average True Range 0.1346
ADX 16.95
+DI 38.3884
-DI 59.5666
Chandelier Exit (Long, 3 ATRs ) 1.0962
Chandelier Exit (Short, 3 ATRs ) 1.0488
Upper Bollinger Band 1.4782
Lower Bollinger Band 0.5872
Percent B (%b) 0.17
BandWidth 86.2787
MACD Line -0.2220
MACD Signal Line -0.2286
MACD Histogram 0.0065
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.7400
Resistance 3 (R3) 0.7400 0.7400 0.7400
Resistance 2 (R2) 0.7400 0.7400 0.7400 0.7400
Resistance 1 (R1) 0.7400 0.7400 0.7400 0.7400 0.7400
Pivot Point 0.7400 0.7400 0.7400 0.7400 0.7400
Support 1 (S1) 0.7400 0.7400 0.7400 0.7400 0.7400
Support 2 (S2) 0.7400 0.7400 0.7400 0.7400
Support 3 (S3) 0.7400 0.7400 0.7400
Support 4 (S4) 0.7400